Page 407 - Binder2

We’ll repeat the same mistakes:

• Sky-high list prices built on legacy pricing models.
• Restricted access via payers and pharmacy benefit
managers.
• Private monopolization of therapies developed
with public trust.

But this new platform offers a chance to start over.

It invites us to design a distribution system that reflects
the abundance of the science itself.

This new ethical model asks:

• Can drugs be priced based on cost of production,
not cost of restriction?
• Can open-source medicine and for-profit
innovation coexist?
• Can we build a world where access is designed in,
not patched on?

Toward a Biologic Commons

What we need now is a vision—a Biologic Commons—a
global framework for ethically distributing edible, locally
manufacturable therapies.

Such a commons could include:

• Open-access gene repositories for plant-based
biologics.
• Community licensing models that prioritize impact
over royalty maximization.

405